DST experts go to famous pharmaceutical enterprises in Sichuan to carry out GMP audit project!
Release time:
2024-10-25
At the end of December, Dust DST arranged FDA GMP experts to conduct FDA cGMP on-site audits of well-known pharmaceutical companies in Sichuan. This audit is a GMP audit of the company's API project. This audit is Dust DST's European and American GMP requirement audit for the new production line just after the enterprise passed the FDA inspection of sterile bulk drugs and sterile preparations in December. This audit involves the comprehensive inspection of three bulk drug production lines and QC and public systems. This is another collaboration between Durst DST and the company after several project collaborations.
At the end of December, Dust DST arranged FDA GMP experts to conduct FDA cGMP on-site audits of well-known pharmaceutical companies in Sichuan. This audit is a GMP audit of the company's API project. This audit is Dust DST's European and American GMP requirement audit for the new production line just after the enterprise passed the FDA inspection of sterile bulk drugs and sterile preparations in December. This audit involves the comprehensive inspection of three bulk drug production lines and QC and public systems. This is another collaboration between Durst DST and the company after several project collaborations.
In recent years, DST DST's expert team has experienced many international GMP certification inspections and has rich experience in dealing with GMP certification inspections. It can help pharmaceutical companies to improve their GMP certification inspections in all aspects and ensure the smooth development and approval of GMP certification inspections. At the same time, DST Durst also has rich experience and many successful cases in the construction of quality system, simulation audit, GMP certification and other aspects, helping many pharmaceutical companies to pass GMP certification. Recently, DST Durst has coached Sichuan Huiyu Pharmaceutical and Chengdu Shengnuo Biology to pass FDA certification in the United States. In addition, most of DST Durst's expert teams have worked in well-known foreign companies in the industry or worked and studied in foreign pharmaceutical companies, with rich experience, innovative ideas and solid professional skills, can bring better customer experience and results for customers.
Since the establishment of DST Durst, DST Durst has taken the mission of enabling more pharmaceutical enterprises to reach the international top quality management level, the concept of customer first, and its own specialty as its hard strength, focusing on serving international GMP consulting work, including FDA, EU-GMP, TGA, PIC/S, QP and other certification, auditing and verification work. It has successively provided international GMP services for Lizhu Pharmaceutical, Baiyunshan Pharmaceutical, China Resources Sanjiu, North China Pharmaceutical, Kangtai Biology, Baiji Biology, Longsha Biology, Sinopharm Zhongsheng and other enterprises, and has been recognized by customers. Has repeatedly used simulation inspection and audit to help pharmaceutical companies through international certification audit and inspection, has helped Huiyu Pharmaceutical, China Resources Sanjiu, Sinopharm, Hanteng Bio, Raffles Pharmaceutical and other pharmaceutical companies through international certification audit and inspection.
Key words:
Related Blog
Durst DST Regulation Group, noting that on July 1, 2024, the Drug Evaluation Center of the State Drug Administration (hereinafter referred to as CDE) issued a trial notice on the submission of electronic application materials for drug registration by network transmission. Starting from July 1, 2024, the trial work on the network transmission of electronic application materials for drug registration will be started, and applicants can submit electronic application materials for drug registration through network transmission. There is also an attachment: the reservation for network transmission of electronic declaration materials and the description of operation steps, which is convenient to guide everyone to submit electronic declaration materials.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Recently, after the products of DST DST customers Sichuan well-known pharmaceutical companies passed PAI inspection in November 2023, they were officially approved in December. In June 2024, they officially sent several batches of products to enter the US market. This exciting news came at the time of the third FDA project audit of the client again. The customer is located in Neijiang City, Sichuan Province, an ancient city between Chengdu and Chongqing. The success of Huiyu Pharmaceutical has made this city more attractive to pharmaceutical people! Once again, congratulations to the customer products officially go to sea! The entry of products into the US market shows that DST customers have been strictly implementing quality management according to high standards, continuously optimizing production processes, and producing more high-quality products higher than national standards.
2024-07-05
Argument! Hengrui Warning Letter, Is It FDA's Political Sanction?
Tieguai Liu saw many posts about whether there were political factors in Hengrui's warning letter. Today, Tieguai Liu will discuss this matter with everyone's concerns. First of all, we are very sensitive to see that the "first brother" of China's pharmaceutical industry has received a warning letter from the FDA of the United States. For today's Sino-US environment, we naturally think of the FDA's sanctions against the first brother due to the influence of US politics. It is completely understandable from everyone's interpretation. The following Tieguai Liu will discuss with you from both positive and negative dimensions:
2024-10-25
Durst DST continues to pay attention to the drug regulatory policies of countries around the world to help companies go to sea, and the following is the drug regulatory situation in Southeast Asian countries and regions.
2024-10-25
Contact Information
Durst (Shenzhen) Consulting Service Co., Ltd.
Contact Phone:86-18826007039
E-mail:consulting@delsalt.com
Address: C19, Building 1, Yongheyuan, Zhuangbian Community, xixiang street, Bao 'an District, Shenzhen City, Guangdong Province
Sweep to identify concerns:
Scan attention consultation